Header Logo

Connection

DAVID GRAHAM to Treatment Outcome

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Treatment Outcome.
DAVID GRAHAM
Connection Strength
2.576
Treatment Outcome
  1. Seizure outcome after corpus callosotomy in a large paediatric series. Dev Med Child Neurol. 2018 02; 60(2):199-206.
    View in: PubMed
    Score: 0.180
  2. Overcoming the effects of increasing antimicrobial resistance on Helicobacter pylori therapy. Expert Rev Gastroenterol Hepatol. 2024 Nov; 18(11):705-711.
    View in: PubMed
    Score: 0.074
  3. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 01; 120(4):787-798.
    View in: PubMed
    Score: 0.073
  4. Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data. Helicobacter. 2024 Jul-Aug; 29(4):e13112.
    View in: PubMed
    Score: 0.072
  5. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
    View in: PubMed
    Score: 0.065
  6. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.056
  7. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021 May; 36(5):1159-1163.
    View in: PubMed
    Score: 0.055
  8. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol. 2019; 1149:211-225.
    View in: PubMed
    Score: 0.049
  9. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019 Feb; 24(1):e12554.
    View in: PubMed
    Score: 0.048
  10. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol. 2019 Jan; 13(1):17-24.
    View in: PubMed
    Score: 0.048
  11. Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience. World J Gastroenterol. 2018 Nov 07; 24(41):4698-4707.
    View in: PubMed
    Score: 0.048
  12. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018 Feb; 154(3):462-466.
    View in: PubMed
    Score: 0.046
  13. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.046
  14. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2018 06; 16(6):800-808.e7.
    View in: PubMed
    Score: 0.045
  15. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017 08; 62(8):1890-1896.
    View in: PubMed
    Score: 0.044
  16. Reply. Clin Gastroenterol Hepatol. 2017 09; 15(9):1480-1481.
    View in: PubMed
    Score: 0.043
  17. New Insight Into an Effective Treatment of Marginal Ulceration After Roux-en-Y Gastric Bypass. Clin Gastroenterol Hepatol. 2017 04; 15(4):501-503.
    View in: PubMed
    Score: 0.043
  18. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016 11; 61(11):3215-3220.
    View in: PubMed
    Score: 0.042
  19. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 06; 14(6):577-85.
    View in: PubMed
    Score: 0.041
  20. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May; 65(5):870-8.
    View in: PubMed
    Score: 0.040
  21. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 05; 150(5):1113-1124.e5.
    View in: PubMed
    Score: 0.040
  22. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 07; 21(45):12954-62.
    View in: PubMed
    Score: 0.040
  23. Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter. 2016 Apr; 21(2):85-90.
    View in: PubMed
    Score: 0.039
  24. Prospective, randomized comparison of 2 methods of cold snare polypectomy for small colorectal polyps. Gastrointest Endosc. 2015 Oct; 82(4):686-92.
    View in: PubMed
    Score: 0.038
  25. Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med. 2015 Mar; 30(2):133-9.
    View in: PubMed
    Score: 0.037
  26. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol. 2014 Sep 07; 20(33):11467-85.
    View in: PubMed
    Score: 0.036
  27. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol. 2014 Sep 07; 20(33):11552-9.
    View in: PubMed
    Score: 0.036
  28. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014 Aug; 19(4):319-22.
    View in: PubMed
    Score: 0.035
  29. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014; 20(28):4510-6.
    View in: PubMed
    Score: 0.035
  30. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014 Jan; 8(1):21-8.
    View in: PubMed
    Score: 0.034
  31. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012 Oct; 17(5):382-90.
    View in: PubMed
    Score: 0.031
  32. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol. 2012 Jan; 27(1):59-61.
    View in: PubMed
    Score: 0.030
  33. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug; 16(4):295-300.
    View in: PubMed
    Score: 0.029
  34. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr; 45(4):309-13.
    View in: PubMed
    Score: 0.029
  35. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr; 16(2):139-45.
    View in: PubMed
    Score: 0.029
  36. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr; 16(2):146-52.
    View in: PubMed
    Score: 0.029
  37. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 Feb; 8(2):79-88.
    View in: PubMed
    Score: 0.028
  38. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol. 2011 May; 9(5):373-5.
    View in: PubMed
    Score: 0.028
  39. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010 Dec; 8(12):1032-6.
    View in: PubMed
    Score: 0.027
  40. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug; 59(8):1143-53.
    View in: PubMed
    Score: 0.027
  41. Obscure gastrointestinal bleeding: where do we go from here? Gastroenterology. 2010 May; 138(5):1655-8.
    View in: PubMed
    Score: 0.027
  42. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010 Aug; 45(8):816-20.
    View in: PubMed
    Score: 0.026
  43. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol. 2010 Mar; 45(3):292-8.
    View in: PubMed
    Score: 0.026
  44. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology. 2010 May; 138(5):1836-44.
    View in: PubMed
    Score: 0.026
  45. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):36-41.e1.
    View in: PubMed
    Score: 0.026
  46. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):145-8.
    View in: PubMed
    Score: 0.024
  47. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.023
  48. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007 Jul; 56(7):1021-3; author reply 1022-3.
    View in: PubMed
    Score: 0.022
  49. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Sep 01; 24(5):845-50.
    View in: PubMed
    Score: 0.021
  50. Is there a role for sequential in sequential anti-H. pylori therapy? Gastroenterology. 2006 May; 130(6):1930-1; author reply 1931.
    View in: PubMed
    Score: 0.020
  51. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.019
  52. Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
    View in: PubMed
    Score: 0.018
  53. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.018
  54. Controversies regarding management of Helicobacter pylori infections. Curr Opin Gastroenterol. 2023 11 01; 39(6):482-489.
    View in: PubMed
    Score: 0.017
  55. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.016
  56. Outcomes of Arthroscopic-Assisted Distal Radius Fracture Volar Plating: A Meta-Analysis. J Hand Surg Am. 2022 04; 47(4):330-340.e1.
    View in: PubMed
    Score: 0.015
  57. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter. 2002 Feb; 7(1):1-8.
    View in: PubMed
    Score: 0.015
  58. Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes. J Gastroenterol Hepatol. 2021 Nov; 36(11):3027-3032.
    View in: PubMed
    Score: 0.015
  59. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021 08; 161(2):495-507.e4.
    View in: PubMed
    Score: 0.014
  60. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
    View in: PubMed
    Score: 0.014
  61. Radiofrequency ablation for Barrett's oesophagus related neoplasia with the 360 Express catheter: initial experience from the United Kingdom and Ireland-preliminary results. Surg Endosc. 2022 01; 36(1):598-606.
    View in: PubMed
    Score: 0.014
  62. Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy. United European Gastroenterol J. 2020 12; 8(10):1155-1162.
    View in: PubMed
    Score: 0.014
  63. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.013
  64. Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer-related bleeding: multicenter international registry. Endoscopy. 2021 01; 53(1):36-43.
    View in: PubMed
    Score: 0.013
  65. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
    View in: PubMed
    Score: 0.013
  66. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci. 2020 12; 65(12):3639-3646.
    View in: PubMed
    Score: 0.013
  67. Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Dig Endosc. 2020 Jan; 32(1):96-105.
    View in: PubMed
    Score: 0.013
  68. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol. 1999 Jul; 37(7):2274-9.
    View in: PubMed
    Score: 0.013
  69. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 06; 49(11):1385-1394.
    View in: PubMed
    Score: 0.012
  70. Achalasia diagnosed despite normal integrated relaxation pressure responds favorably to therapy. Neurogastroenterol Motil. 2019 06; 31(6):e13586.
    View in: PubMed
    Score: 0.012
  71. Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. Gut Microbes. 2019; 10(4):504-520.
    View in: PubMed
    Score: 0.012
  72. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 1999 Jan; 13(1):35-42.
    View in: PubMed
    Score: 0.012
  73. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis. 2018 Nov; 19(11):674-677.
    View in: PubMed
    Score: 0.012
  74. A randomized comparison of dilatation alone versus dilatation plus laser in patients receiving chemotherapy and external beam radiation for esophageal carcinoma. Dig Dis Sci. 1998 Oct; 43(10):2255-60.
    View in: PubMed
    Score: 0.012
  75. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 06; 47(11):1453-1463.
    View in: PubMed
    Score: 0.012
  76. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 04; 70(4):537-546.
    View in: PubMed
    Score: 0.012
  77. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018 09; 16(9):1427-1433.
    View in: PubMed
    Score: 0.012
  78. Update on Helicobacter pylori research. Eradication. Eur J Gastroenterol Hepatol. 1997 Jun; 9(6):626-8.
    View in: PubMed
    Score: 0.011
  79. An objective end point for dilation improves outcome of peptic esophageal strictures: a prospective randomized trial. Gastrointest Endosc. 1997 May; 45(5):354-9.
    View in: PubMed
    Score: 0.011
  80. Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy. 2015 Nov; 47(11):980-7.
    View in: PubMed
    Score: 0.010
  81. Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett's associated neoplasia. Scand J Gastroenterol. 2015; 50(11):1315-21.
    View in: PubMed
    Score: 0.009
  82. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Apr; 9(2):209-12.
    View in: PubMed
    Score: 0.009
  83. Prospective randomized comparison of polyvinyl bougies and through-the-scope balloons for dilation of peptic strictures of the esophagus. Gastrointest Endosc. 1995 Mar; 41(3):189-95.
    View in: PubMed
    Score: 0.009
  84. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.009
  85. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993 Jun; 24(6):577-83.
    View in: PubMed
    Score: 0.008
  86. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013 Oct; 18(5):373-7.
    View in: PubMed
    Score: 0.008
  87. Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):319-25.
    View in: PubMed
    Score: 0.007
  88. Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):326-32.
    View in: PubMed
    Score: 0.007
  89. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun; 71(7):1200-1203.e2.
    View in: PubMed
    Score: 0.007
  90. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009 Apr; 14(2):109-18.
    View in: PubMed
    Score: 0.006
  91. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009 Apr; 157(4):606-12.
    View in: PubMed
    Score: 0.006
  92. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007 Dec; 16(12):1275-84.
    View in: PubMed
    Score: 0.006
  93. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther. 2006 Jan 15; 23(2):295-301.
    View in: PubMed
    Score: 0.005
  94. Schatzki's ring: to cut or break an unresolved problem. Dig Dis Sci. 2004 Mar; 49(3):379-83.
    View in: PubMed
    Score: 0.004
  95. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003 Dec; 8(6):626-42.
    View in: PubMed
    Score: 0.004
  96. Sustained increase in gastric antral epithelial cell proliferation despite cure of Helicobacter pylori infection. Am J Gastroenterol. 2000 Apr; 95(4):930-5.
    View in: PubMed
    Score: 0.003
  97. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996 Dec; 1(4):243-50.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.